Illness	Number of cases
Undescended testicle (Q53.1)	27
Inguinal hernia - Unilateral inguinal hernia without obstruction or gangrene not specified as recurrent (K40.90)	9
Congenital obstructive defects of renal pelvis and congenital malformations of ureter - Congenital hydronephrosis (Q62.0)	7
Abscess of anal and rectal regions - Anal abscess (K61.0)	4
Obstructive and reflux uropathy (N13.7)	4
Benign lipomatous neoplasm (D17.2)	not specified
Haemangioma and lymphangioma any site - Hemangioma of skin and subcutaneous tissue (D18.01)	not specified
Other benign neoplasms of connective and other soft tissue (D21.1)	not specified
Melanocytic naevi - Melanocytic nevi of trunk (D22.5)	not specified
Benign neoplasm of eye and adnexa (D31.9)	not specified

Top 10 treatments

Treatment	Number
Regional pain control by injecting an anaesthetic into a space in the spinal canal (epidural space) (8-910)	23
Surgical fixation of the testicle in the scrotum (5-624.4)	18
Surgical transposition of a testicle lying in the abdomen down into the scrotum (5-626.2)	7
Intensive care monitoring of respiration, the heart and the circulation without measurement of the pressure in the pulmonary artery and in the right atrium of the heart (8-930)	7
Surgical repair of an inguinal hernia (5-530.00)	6
Surgical repair of an inguinal hernia (5-530.31)	6
Type of material used for tissue replacement and tissue reinforcement (5-932.40)	6
Surgical incision into or removal of tissue from the anus (5-490.0)	5
Examination of the oesophagus, stomach and duodenum by endoscopy (1-632.0)	4
Operation on the foreskin of the penis (5-640.5)	4

Further information about the department

Out-patient accident insurance doctor approval

In-patient Employers’ Liability Insurance Association approval

Department key

Department key: 1300

Type of specialist department

Main Department

Hospital information and services for all specialist departments

Services

Quality

External comparative quality assurance

Further information

External quality assurance according to state law
No participation

Quality of participation in the Disease Management Programme (DMP)
No participation

Teilnahme an sonstigen Verfahren der externen vergleichenden Qualitätssicherung

Implementation of resolutions of the Federal Joint Committee on quality assurance (G-BA)

No.	Explanation
CQ02
CQ05

Further training
pursuant to Article 136b, para. 1, sentence 1, no. 1 of the SGB

Number	Group
9	Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
7	Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
4	Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations

* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

Accessibility

Accessibility information

General information

Research & teaching

Job	Explanation
Doctoral supervision	Abschluss einer Dissertation für Uni Jena 10.2023 (Prof. Mainz) 5 DoktorandInnen der MHB (Prof. Mainz)
Student training (clinical traineeship / internship year)	14 Famulanten und 3 PJler auf Stationen der Kinderklinik KWB-Brandenburg
Lectureships / teaching posts at universities of applied sciences
Lectureships / teaching posts at colleges and universities	Prof. Mainz, berufen W2-MHB; Chefarzt Dr. Kössel Vorlesungen MHB; Oberärzte der Kinderklinik: Kurse für Pädiatrie 5. und 8. Semester MHB
Editors of scientific journals/textbooks	Prof. Dr. J.G. Mainz: 8 Artikel in internationalen Peer-Reviewed Journals
Project-related cooperation with colleges and universities	Kooperationspartner für Studien mit CFAbd-Score: D: Potsdam, Uni Frankfurt, Gießen, Tübingen International: Sydney, Toronto, Dublin (Irl.), London, Leeds, Nottingham (UK), Paris (F), Zürich (CH), Ghent (Belgien), Thessaloniki (Griechenland), Campinas (Brasilien), Santa Fe (Argentinien)
Participation in multi-centre phase III/IV studies	Principal Investigator: VX20-CFD-005; VX21-445-123: Co Investigator; 2021-000190-81: Principal Investigator; 2020-005805-25: Co-Investigator; 2021-000712-31: Co-Investigator